Overview of drug control: A regulatory primer on scheduling and controlled substance regulations

Clinical Research and Regulatory Affairs

Volumn 23, Issue 3-4, 2006, Pages 211-225

  Parker, Jonathon M ^a  

^a UNIVERSITY OF RHODE ISLAND   (United States)

Author keywords

Abuse Liability; Abuse Potential; Controlled Substances; Drug Development; Drug Scheduling; Review

Indexed keywords

ANTIBIOTIC AGENT; CEPHALOSPORIN; ESZOPICLONE; PREGABALIN;

CHEMICAL ANALYSIS; CLINICAL STUDY; DRUG ABUSE; DRUG CONTROL; DRUG LEGISLATION; DRUG MARKETING; DRUG USE; HUMAN; MEDICAL LIABILITY; NONHUMAN; PRESCRIPTION; REVIEW;

EID: 33847112769     PISSN: 10601333     EISSN: 15322521     Source Type: Journal    
DOI: 10.1080/10601330601079851     Document Type: Review

References (28)

1. Code of Federal Regulations, Title 21, Part 314.50.
2. Code of Federal Regualtions, Title 21, Chapter 13, Subchapter I, Part A, Section 801, (2).
3. Pure Food and Drug Act, 34 Stat. 768, 1906.
4. Pure Food and Drug Act, 34 Stat. 768, 1906, Section 7.
5. Pure Food and Drug Act, 34 Stat. 768, 1906, Section 8.
6. 21 U.S.C. 352(d), Section 502(d) repealed, February 19, 1998.
7. 21 USC 801, Pub. L. 91-513, title II, Sec. 101, Oct. 27, 1970, 84 Stat. 1242. and 21 USC 801a, Pub. L. 95-633, title I, Sec. 101, Nov. 10, 1978, 92 Stat. 3768; Pub. L. 96-88, title V, Sec. 509(b), Oct. 17, 1979, 93 Stat. 695.
8. 21 USC 801, Pub. L. 91-513, title II, Sec. 101, Oct. 27, 1970, 84 Stat. 1242.
9. Joranson DE. NIDA Monograph 131, 1993:18.
10. Code of Federal Regulations, Title 21, Section 811(a).
11. Code of Federal Regulations, Title 21, Section 812(b).
12. Code of Federal Regulations, Title 21, Section 811(c).
13. Code of Federal Regulations, Title 21, Part C.
14. Code of Federal Regulations, Title 21, Section 822.
15. Code of Federal Regulations, Title 21, Section 826.
16. Code of Federal Regulations, Title 21, 829(a) and 829(b).
17. Vocci, FJ. NIDA Monograph 92, 1989:,7.
18. Glennon RA. NIDA Monograph 116, 1991:1.
19. Malanga CJ, Kosofsky BE. Does drug abuse beget drug abuse? Behavoiral analysis of addiction liability in models of prenatal drug exposure. Dev Brain Res 2003; 147:47-57.
20. Spanagel R, Sanchis-Segura C. The use of transgenic mice to study addictive behavior. Clin Neurosci Res 3 2003: 325-331.
21. Jackson HC, Nutt DJ. A single preexposure produces sensitization to locomotor effects of cocaine in mice. Pharmacol Biochem Behav 1993 Jul; 45(3):733-735.
22. Vanderschruen LJ De Vries TJ, Wardeh G, Hogenboom FA, Schofeelmeer AN. A single exposure of morphine induces long lasting behavorial and neurochemical sensitization in rats. Eur J Neurosci 2001; 14:1533-1538.
23. Leiderman D. FDA Workshop, 62nd Annual Meeting of the CPDD, San Juan, Puerto Rico, June 18, 2000.
24. Jaffe FK, Jaffe JH. NIDA Monograph 92, 1989:63-64.
25. Dews P. Remarks. In: Thompson T, Unna KR, eds. Predicting Dependence Liability of Stimulant and Depressant Drugs. Baltimore: University Park Press, 1977:75-79.
26. Code of Federal Regulations, Title 21, 312.21(a).
27. Code of Federal Regulations, Title 21, 312.21(c).
28. Code of Federal Regulations, Title 21, 314.50(5)(vii).